Collegium Pharmaceutical (COLL) Return on Capital Employed (2015 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Return on Capital Employed of 15.49% for Q1 2026, up 324.0% year-over-year from 3.65% in Q1 2025, and up 2.77% quarter-over-quarter from 15.07% in Q4 2025.
Collegium Pharmaceutical (COLL) Return on Capital Employed (2015 - 2026) Analysis & Trends
Collegium Pharmaceutical's Return on Capital Employed history runs 12 years deep, the most recent figure standing at 15.49% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 324.0% year-over-year to 15.49%; the TTM figure through Mar 2026 stood at 15.49% (up 324.0% YoY), while the FY2025 annual figure was 14.72%, down 428.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 15.49%, up from 15.07% in the prior quarter.
- The five-year high for Return on Capital Employed was 32.74% in Q2 2024, with the low at 2.28% in Q1 2022.
- The 5-year median for Return on Capital Employed is 13.69% (2025), against an average of 13.18%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 2086 bps in 2024, then sank 2143 bps in 2025.
- Collegium Pharmaceutical's Return on Capital Employed stood at 4.42% in 2022, then jumped by 438 bps to 23.77% in 2023, then slumped by 37 bps to 14.9% in 2024, then increased by 1 bps to 15.07% in 2025, then rose by 3 bps to 15.49% in 2026.
- Business Quant data shows COLL's Return on Capital Employed at 15.49% in Q1 2026, 15.07% in Q4 2025, and 13.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Collegium Pharmaceutical | 887.15 Mn | 737.84 Mn | 110.29 Mn | 12.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.07% |
| Mar 31, 2026 | 15.49% |
| Dec 31, 2025 | 15.07% |
| Sep 30, 2025 | 13.69% |
| Jun 30, 2025 | 11.31% |
| Mar 31, 2025 | 12.24% |
| Dec 31, 2024 | 14.90% |
| Sep 30, 2024 | 21.87% |
| Jun 30, 2024 | 32.74% |
| Mar 31, 2024 | 28.11% |
| Dec 31, 2023 | 23.77% |
| Sep 30, 2023 | 16.01% |
| Jun 30, 2023 | 11.87% |
| Mar 31, 2023 | 8.70% |
| Dec 31, 2022 | 4.42% |
| Sep 30, 2022 | -1.55% |
| Jun 30, 2022 | -2.27% |
| Mar 31, 2022 | -2.28% |
| Dec 31, 2021 | 4.03% |
| Sep 30, 2021 | 14.55% |